Efforts to develop sEH inhibitors have made available numerous compounds that show therapeutic efficacy and a wide margin of safety in a variety of different diseases, including non-alcoholic fatty liver disease, liver fibrosis, portal hypertension, and others. The gene discussed is EPHX2; the disease is metabolic dysfunction-associated steatotic liver disease.